1353557-68-2Relevant academic research and scientific papers
MACROLACTAM COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA
-
, (2012/11/06)
The present invention relates to a macrolactam compound, and methods for treating a subject with malaria using the macrolactam compound, represented by the following structural formula (l), wherein the values and preferred values of the variables are defined herein.
Diversity-oriented synthesis yields a novel lead for the treatment of malaria
Heidebrecht Jr., Richard W.,Mulrooney, Carol,Austin, Christopher P.,Barker Jr., Robert H.,Beaudoin, Jennifer A.,Cheng, Ken Chih-Chien,Comer, Eamon,Dandapani, Sivaraman,Dick, Justin,Duvall, Jeremy R.,Ekland, Eric H.,Fidock, David A.,Fitzgerald, Mark E.,Foley, Michael,Guha, Rajarshi,Hinkson, Paul,Kramer, Martin,Lukens, Amanda K.,Masi, Daniela,Marcaurelle, Lisa A.,Su, Xin-Zhuan,Thomas, Craig J.,Weiwer, Michel,Wiegand, Roger C.,Wirth, Dyann,Xia, Menghang,Yuan, Jing,Zhao, Jinghua,Palmer, Michelle,Munoz, Benito,Schreiber, Stuart
supporting information; experimental part, p. 112 - 117 (2012/04/04)
Here, we describe the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites. Screening a novel compound collection created using diversity-oriented synthesis (DOS) led to the initial hit. Structure-activity relationships guided the synthesis of compounds having improved potency and water solubility, yielding a subnanomolar inhibitor of parasite asexual blood-stage growth. Optimized compound 27 has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma. This compound is available via the molecular libraries probe production centers network (MLPCN) and is designated ML238.
